Johnson & Johnson

J&J gets plaintiff backing for $6.5 bn to resolve lawsuits over baby powder

Separately, the company said in May it has resolved 95% of claims its baby powder was tainted with asbestos and caused mesothelioma, a type of cancer that forms in tissues around the heart and lungs

Johnson & Johnson Q2 profit beats expectations as forecast cut on M&A costs

Adjusted earnings for the quarter were $2.82 a share, the New Brunswick, New Jersey-based company said Wednesday in a statement, beating analysts' average estimate by 11 cents

J&J subsidiary proposes paying $6.48 bn over 25 yrs to settle talc lawsuits

A subsidiary of Johnson and Johnson is now proposing paying approximately USD 6.48 billion over 25 years as part of a settlement to cover allegations that its baby powder containing talc caused ovarian cancer. The lawsuits filed against JandJ had alleged its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs. JandJ said that the reorganization plan for the subsidiary that was being announced on Wednesday was significantly different from the previous reorganization that was announced. Those differences include a three-month solicitation period during which ovarian claimants can vote for or against the plan. This is something that was denied in prior bankruptcy cases, the company said. And if 75 per cent of claimants vote in favor of the plan, a subsidiary may file a prepackaged Chapter 11 bankruptcy to secure its confirmation. The remaining pending personal injury lawsuits that rel

Johnson & Johnson to buy equipment maker Shockwave Medical for $12.5 bn

Under the deal, J&J would pay $335 per share in cash for the medical device maker. The offer price implies a 4.7% premium to Shockwave's last close of $319.99 on Thursday

J&J's immune disorder drug succeeds in mid and late-stage studies

The drug, nipocalimab, significantly reduced symptoms of generalized myasthenia gravis (gMG) in a late-stage study, and in a mid-stage study helped reduce Sjogren's disease severity, J&J said

P&G Hygiene Q2 result: Profit jumps as lower costs offset dip in sales

BENGALURU (Reuters) - Indian consumer goods maker Procter & Gamble Hygiene and Health Care reported higher second-quarter net profit on Wednesday, as lower costs countered a small drop in sales.

Talc lawsuit: J&J sets up 3rd bankruptcy bid by moving unit to Texas

The company filed a request last month with the Texas secretary of state's office to relocate its LTL Management unit to Austin and rename it ahead of a Chapter 11 filing in the state

Johnson & Johnson sees 2024 sales growth slowing as top drug faces rivals

The pharma and medical devices giant will soon lose its exclusivity with psoriasis treatment Stelara, which accounted for a fifth of its drug sales in the third quarter

J&J weighs third bankruptcy try to settle baby powder cancer case

Attorneys for some plaintiffs opposed the idea of a return to bankruptcy court

J&J raises profit forecast as it bets on cancer drugs, medical devices

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose about 2% in premarket trading

Johnson&Johnson ordered to pay $18.8 mn in California talc-cancer trial

Jurors in state court in state court in Oakland concluded Tuesday that J&J's baby powder helped cause Anthony Hernandez Valadez's mesothelioma, a specific type of cancer linked to asbestos exposure

J&J, cancer victims ordered to start settlement talks in bankruptcy

A federal judge ordered a new round of settlement talks between Johnson & Johnson and lawyers who spurned the company's offer to pay $8.9 billion to end tens of thousands of cancer claims

J&J accused by US of misusing bankruptcy to end talc cancer suits

J&J has an $8.9 billion settlement agreement with the "vast majority" of the law firms representing talc claimants, said the company's head of litigation

J&J accused by US of misusing bankruptcy to end talc cancer suits

The healthcare products maker is trying for the second time to get itself out of a jam as cheaply as possible, using the Chapter 11 filing of LTL Management

J&J unit says cancer victims who won't settle seek to block $8.9 bn deal

LTL has the backing of 60,000 victims, or about two thirds of all claimants, lawyer Gregory M. Gordon said in federal court on Tuesday

India's TB programme: Low cost generics of J&J's MDR-TB drug on the anvil

Indian Patent Office's decision on J&J's bedaquiline came on the eve of World Tuberculosis Day, marked on March 24 every year, to raise public awareness & to boost efforts to end the TB epidemic

J&J forecasts strong profit, beats Wall Street estimates on pharma boost

Shares of the drugmaker were up nearly 1% at $170.28 in trading before the bell

Bombay HC permits Johnson & Johnson to manufacture, sell baby powder

The Bombay High Court on Wednesday quashed two orders passed by the Maharashtra government revoking the license of Johnson & Johnson company to manufacture, sell and distribute its baby powder products, terming them as stringent, unreasonable and unfair. A division bench of Justices Gautam Patel and S G Dige permitted the company to manufacture, sell and distribute the products. The bench passed its order on a petition filed by the company challenging two orders of the state government one dated September 15, 2022 cancelling the license and the second dated September 20, 2022 ordering it to immediately stop the manufacturing and sale of the baby powder product. The bench noted that while maintaining standards of quality and safety are of utmost importance for cosmetic products, at the same time it does not seem reasonable to shut down the whole manufacturing process when there is a slight deviation in one of the products. "The executive cannot use a hammer to kill an ant. Is it ..

Patchy recovery: How 2022 swung from despair to hope to caution

Even as it grappled with new viruses, the human race hit another milestone

J&J to buy cardiovascular technology Abiomed in $16.6 billion deal

Johnson and Johnson will spend USD 16.6 billion to buy cardiovascular technology company Abiomed to strengthen its medical device division. The health care giant said on Tuesday that it will pay USD 380 for each Biomed share and also provide another USD 35 per share in cash if some commercial and clinical milestones are met. Abiomed develops technology that treats coronary artery disease and heart failure.